RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company, announced last week that its U.S. joint venture partner and Pan Asian licensee, GtreeBNT, has been granted a new U.S. patent for a method of preventing or treating dry eye syndrome. The treatment is to administer Tβ4 with non-active ingredients to provide improved pharmacodynamics. Tβ4 is the active component of RGN-259, currently in separate phase 3 clinical trials for dry eye syndrome and neurotrophic keratitis. The expiry of this new patent is 2035.
RGN-259 eye drops contain an active small protein, thymosin beta 4, which is naturally occurring in tears and other body fluids. RGN-259 eye drops have demonstrated wide-ranging and multifunctional activities. Such activities underlie the efficacy of RGN-259 eye drops seen to date in alleviating both the signs and symptoms of dry eye. The eye drops are safe and well-tolerated by patients, and in both ARISE-1 and ARISE-2 clinical trials, patients reported minimal ocular discomfort similar to that of the placebo. RGN-259 is currently the subject of a 700-patient phase 3 clinical trial in the U.S, ARISE-3.
RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, three active strategic licensing agreements in the U.S., China, and Pan Asia (Korea, Japan, and Australia, among others), and has patents and patent applications covering its products in many countries throughout the world. RGN-259, the Company's ophthalmic eye drop, is currently in Phase 3 clinical trials for dry eye syndrome and neurotrophic keratopathy.
News source: http://www.regenerx.com/2019-05-16-RegeneRx-Partner-Receives-Patent-for-New-Ophthalmic-Formulation-of-Thymosin-Beta-4
Source: RegeneRx Biopharmaceuticals